Why Ocular Therapeutix, Inc.’s (OCUL) Stock Is Down 11.87%
As of Monday, September 28, Ocular Therapeutix, Inc.’s OCUL share price has dipped by 11.87%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
Commentary & Analysis
Why Ocular Therapeutix, Inc.’s (OCUL) Stock Is Down 19.90%
As of Monday, September 28, Ocular Therapeutix, Inc.’s OCUL share price has dipped by 19.90%, which has investors questioning if this is right time to buy.Omar Beirat
Why Ocular Therapeutix, Inc.’s (OCUL) Stock Is Up 6.53%
As of Thursday, September 17, Ocular Therapeutix, Inc.’s OCUL share price has surged by 6.53%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Which Is a Better Investment, Ocular Therapeutix, Inc. or Trulieve Cannabis Corp. Stock?
Learn more about whether Ocular Therapeutix, Inc. or Trulieve Cannabis Corp. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Rosalio Madrigal
Why Ocular Therapeutix, Inc.’s (OCUL) Stock Is Up 5.81%
As of Tuesday, September 08, Ocular Therapeutix, Inc.’s OCUL share price has surged by 5.81%, which has investors questioning if this is right time to sell.Jenna Brashear
Financial Summary
| Share Statistics | OCUL | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,655.9 | $519.2 | 52% |
|
| Shares Out (Mil) | 225.0 | 42.8 | 78% |
|
| Institutional Ownership | 98.5% | 82.8% | 79% |
|
| Float (Mil) | 184.7 | 44.4 | 72% |
|
| Beta | 0.97 | 0.71 | 58% |
|
| Avg Daily Volume (000s) | 5,266 | 394 | 92% |
|
| Price Change (52-week) |
(36.7%) | 60.2% | 25% |
|
| Growth | OCUL | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 24.5% | 6.1% | 86% |
|
| Net Income (5yr) | (11.3%) | (2.0%) | 28% |
|
| EPS (5yr) | 11.1% | 15.0% | 49 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (8.4%) | (15.1%) | 59% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 5 | 4 | 5 | |
| Current EPS | ($0.352) | ($1.430) | ($1.454) | |
| Month Ago EPS | ($0.352) | ($1.430) | ($1.454) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 0 | 0 | |
| Three Months Ago EPS | ($0.388) | ($1.553) | ($1.538) | |
| Year/Year Chg | 0.6% | 0.7% | (27.5%) | |
| Financials | OCUL | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $52 | $416 | 20% |
|
| Net Income (TTM) (Mil) | ($301) | ($11) | 5% |
|
| EPS (TTM) | ($1.409) | ($0.700) | 18% |
|
| Operating Cash Flow (TTM) (Mil) | ($238) | ($7) | 3% |
|
| Net Cash Flow (TTM) (Mil) | $208 | $6 | 84% |
|
| Long-Term Debt (Q1) (Mil) | $76 | $6 | 42% |
|
| Enterprise Value (Q1) (Mil) | $1,675 | $494 | 47% |
|
| Valuation | OCUL | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.18 | 2.31 | 69% |
|
| P/E | na | 17.4 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | OCUL | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (342.3%) | 69.4% | 1% |
|
| Net Margin | (579.1%) | 3.2% | 1% |
|
| ROA | (53.7%) | (22.2%) | 11% |
|
| ROE | (73.0%) | (21.4%) | 12% |
|
| Liabilities to Assets | 22.5% | 32.8% | 15% |
|
| F-Score | 2 | 3 | 7% |
|
Ocular Therapeutix, Inc. did not pass any screens on 10/9/2026.
